Olagoke Kolapo
Psychiatric/Mental Health, Community · Tampa, FLNPI 1215406657
Payments from drug & device makers
Across 207 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$677
- Teva Pharmaceuticals USA, Inc.$669
- Alkermes, Inc.$450
- Neurocrine Biosciences, Inc.$412
- E.r. Squibb & Sons, L.L.C.$410
- Otsuka America Pharmaceutical, Inc.$341
- plus $767 from 7 others
What the payments were for
- Food & beverage$3,57996%
- Education$1484%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 34 | $677 |
| Teva Pharmaceuticals USA, Inc. | 54 | $669 |
| Alkermes, Inc. | 19 | $450 |
| Neurocrine Biosciences, Inc. | 17 | $412 |
| E.r. Squibb & Sons, L.L.C. | 19 | $410 |
| Otsuka America Pharmaceutical, Inc. | 22 | $341 |
| AbbVie | 15 | $306 |
| Indivior Inc. | 15 | $247 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $135 |
| Lundbeck LLC | 2 | $35 |
| Sage Therapeutics, LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$125
How this compares
Too few psychiatric/mental health, community providers in Floridato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 35 | $91,900 |
| Abilify MaintenaAripiprazole | 12 | $26,548 |
| VraylarCariprazine Hcl | 11 | $15,620 |
| Aripiprazole | 96 | $7,958 |
| Hydroxyzine Pamoate | 228 | $3,854 |
| Risperidone | 241 | $2,928 |
| Trazodone Hcl | 242 | $2,788 |
| Benztropine Mesylate | 232 | $2,490 |
| Fluphenazine Hcl | 36 | $2,484 |
| Divalproex Sodium | 122 | $2,279 |
| Quetiapine Fumarate | 127 | $2,188 |
| Bupropion XlBupropion Hcl | 93 | $2,101 |
| Buspirone Hcl | 154 | $1,803 |
| Haloperidol Decanoate | 19 | $1,779 |
| Hydroxyzine Hcl | 51 | $1,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $677 | $91,90035 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $341 | $26,54812 claims |
| AbbVieVraylar | $306 | $15,62011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, community providers in Floridaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.